Grace Therapeutics (GRCE) Analyst & Key Data

Analyst Consensus

Buy1 analysts

Buy

Updated Sep 12, 2026

Total Analysts1

Buy

2

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.22

Median Target+80.18%

$4.00

Potential upside vs current price

DCF Value-67.80%

$0.71

Potential downside vs current price

Current Stock Price

$2.22

Median Target+80.18%

$4.00

Potential upside vs current price

DCF Value-67.80%

$0.71

Potential downside vs current price

Analyst Consensus

Buy1 analysts

Buy

Updated Sep 12, 2026

Total Analysts1

Buy

2

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.22

Median Target+80.18%

$4.00

Potential upside vs current price

DCF Value-67.80%

$0.71

Potential downside vs current price

Current Stock Price

$2.22

Median Target+80.18%

$4.00

Potential upside vs current price

DCF Value-67.80%

$0.71

Potential downside vs current price

Grace Therapeutics, Inc.